Tandem Diabetes Care, Inc. TNDM posted a third-quarter 2024 loss of 36 cents per share compared with the year-ago quarter’s ...

Metabolism-targeting injections could pave the way for a new treatments, detection and prevention of bowel cancer ...

Novartis also beat third-quarter earnings and revenue estimates, driven by a year-over-year increase in sales of key drugs.

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...

Adjusted per-share earnings were 90 cents, beating the 76 cents that analysts were looking ... which was cleared by the Food and Drug Administration for people with type 2 diabetes in August -- helped ...

Insulet (Nasdaq:PODD) once again posted significant year-over-year growth as Omnipod revenues continue to rise.

Managing a chronic illness like diabetes isn’t easy, especially with the day-to-day demands of parenting. If you’re a parent living with diabetes in Singapore, balancing your health and family life ...

Please verify your email address. After beating Metaphor ReFantazio and watching the curtain fall on an 80+ hour-long story, players might be wondering what to do next. Reaching the finish line ...

Beau Ehlschide, a student at Country Heights Elementary School, has been selected as a Peyton Manning Children’s Hospital ...

On Monday, Owens & Minor Inc. (NYSE:OMI) reported the third quarter of 2024 adjusted EPS of $0.42, down from $0.44 reported a ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but ...